Navigation Links
Scioderm Appoints Orphan Product Executives to Board of Directors
Date:12/2/2013

DURHAM, N.C., Dec. 2, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors.

As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience. His personal drive, commitment and overall determination to find cures for rare diseases such as Pompe and Fabry Disease will substantially contribute to the overall success of Scioderm.

William (Bill) Aliski brings over 25 years of senior executive orphan drug commercial management experience most recently with FoldRx Pharmaceuticals, Inc. Prior to that he was General Manager for Biomarin Europe and directed the launch of Naglazyme for MPS VI.  He has played a critical leadership role in the launch of other orphan products having spearheaded market access and pricing strategies for companies such as Genzyme and TKT.

"I am most pleased to join the Board of Scioderm and to support the company in its realization of  its mission and objectives for its lead orphan pediatric product SD-101 for the treatment of all subtypes of Epidermolysis Bullosa, a rare and debilitating pediatric disease," noted John Crowley.  "I hope that my experience and perspectives in the orphan drug space can contribute to ensuring the rapid and successful development of this exciting new compound for people living with EB."

Bill Aliski commented, "I look forwarded to working with the management and Board of Scioderm particularly in supporting the company with the definition and execution of its global commercialization strategy including market access and pricing  for its epidermolysis bullosa program, an orphan disease area for which there is currently no treatment and significant  unmet need."

"Both John and Bill will be very strong and complementary additions to Scioderm's Board of Directors, based on their extensive experience in the rare disease and orphan drug arena," said Dr. Robert Ryan, Chief Executive Officer of Scioderm.  "We look forward to their support and insights towards the realization of the company's planned success. I also wish to thank Christos Richards of Levin & Company, an executive search firm specializing in the life sciences field, for leading the effort in securing the new board members."

Chris Christoffersen, Chairman of the Scioderm Board and General Partner of Morgenthaler Ventures, Scioderm's lead investor commented, "To have two distinguished veterans with extensive experience in orphan diseases join our Board is a wonderful event for Scioderm, and we look forward to working with them to make Scioderm a significant success."

Roger Quy, Board Member and General Partner of Technology Partners commented, "I am delighted that Scioderm has attracted these two outstanding individuals in the field of rare diseases to the Board. It is another indication that the contribution of the Company is becoming more broadly recognized." 

About Scioderm and SD-101

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including orphan products. The lead product, SD-101,is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes.  In addition, Scioderm recently received Breakthrough Therapy Designation for SD-101 for treatment of the skin effects in patients with EB, placing the product in a category that may enable expediting of the development program.  The company is headquartered in Durham, North Carolina.  Additional information about Scioderm can be found at www.sderm.com

Scioderm Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks.  Actual results may differ materially from those projected.  These forward-looking statements represent our judgment as of the date of the release.  Scioderm disclaims any intent or obligation to update these forward-looking statements.

Company Contact

Robert Coull
Chief Operating Officer
robert.coull@sderm.com
(919)-824-2594


'/>"/>
SOURCE Scioderm
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scioderm, Inc. Named a 2013 "Fierce Top 15" Company by FierceBiotech
2. Atlas Appoints David Whitaker as Operations Director
3. CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
4. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
5. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
6. Convoy Therapeutics Appoints Clinical Advisory Board
7. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
8. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
9. ACTUS Appoints New Members to Its Management Team
10. Immune Design Appoints Stephen R. Brady Chief Business Officer
11. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... December 5, 2016 The U.S. ... almost $108 billion of revenue and some $890 billion ... spent on global biopharmaceuticals, and this figure is expected ... has lined up these four equities for assessment: Northwest ... Inc. (NASDAQ: ACAD ), Acorda Therapeutics Inc. ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies being ... (ASH) Annual Meeting and Exposition in San ... methods to improve the delivery of life-saving treatments to ... methods are designed to carry therapies directly to the ... which could provide a substantial advantage over traditional, systemic ...
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
Breaking Biology News(10 mins):